Telix Reports the Acquisition of ARTMS and its Advanced Isotope Production Platform
Shots:
- Telix has signed an agreement to acquire ARTMS along with its manufacturing plant & stockpile of ultra-pure rare metals for the production of consumable target
- Telix will make an upfront payment of $15.0M in cash & $42.5M as equity (5,674,636 of its common stocks), $24.5M as development & commercial milestones plus net sales-based low-single to low-double-digit percentages cash earn-outs for ARTMS or Telix products developed using ARTMS products
- Furthermore, the deal also includes ARTMS’ cyclotron-based isotope production system, QUANTM Irradiation System (QIS), used to produce medical isotopes such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) & copper-64 (64Cu)
Ref: Telix Pharmaceuticals | Image: Telix Pharmaceuticals
Related News:- Telix to Acquire QSAM Biosciences to Enhance its Oncology Segment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
